IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Beschreibung
In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.
2 Monate für 1 €
Dann 4,99 € / Monat · Jederzeit kündbar
- Podcasts nur bei Podimo
- 20 Stunden Hörbücher / Monat
- Alle kostenlosen Podcasts
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option-Community!